Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in Moderate-to-Severe Atopic Hand Eczema
NCT05958407Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of tralokinumab in atopic hand eczema (AHE), sponsored by LEO Pharma. Started Aug 2023; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic hand eczema (AHE)
Beyond the preview
Go deeper on NCT05958407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958407.